Medical devices for the delivery of therapeutic aerosols to the lungs

Inhalation Aerosols: Physical and Biological Basis for Therapy

Volumn , Issue , 2006, Pages 417-444

  Dalby, Richard N ^a   Hickey, Anthony J ^b   Tiano, Susan L ^c  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350252363     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (138)

1. Davis DS. Pharmacokinetics of inhaled substances. Scand J Respir Dis 1975; 103(suppl):44-49.
2. Newman SP, Pavia D, Moren F, Sheahan NF, Clark SW. Deposition of pressurized aerosols in the human respiratory tract. Thorax 1981; 36:52-55.
3. Cyr TD, Graham SJ, Li KY, Lovering EG. Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res 1991; 8:658-660.
4. Sethi SK, Norwood DL, Haywood PA, Prime D. Impact of extractable testing on MDI development programs. J Biopharm Sci 1992; 3(1-2):63-68.
5. Dalby RN, Byron PR, Shepherd HR, Papadopoulos E. CFC propellant substitution: P-134a as a potential replacement for P-12 in MDIs. Pharm Technol 1990; 14:26-33.
6. Fisher FX. CFC propellant substitution: International perspectives. Pharm Technol Int 1989; 1(2):16-18.
7. Metered-Dose Inhalers. U.S. Food and Drug Administration. 2005.
8. Atkins PJ. The development of new solution metered dose inhaler delivery systems. In: Proceeding of the Second Annual Respiratory Drug Delivery Symposium. University of Kentucky, Lexington, KY, U.S.A., 1990:416-445.
9. Dalby RN and Byron PR. Comparison of output particle size distributions from pressurized aerosols formulated as solutions or suspensions. Pharm Res 1988; 5(1):36-39.
10. Bell JH, Brown K, Glasby J. Variation in delivery of isoprenaline from various pressurized inhalers. J Pharm Pharmacol 1973; 25(Suppl):32-36.
11. Dalby RN. Special considerations in the formulation of suspension type metered dose inhalers. Aerosol Age 1992:22-89.
12. Byron PR. Aerosol formulation, generation and delivery using metered systems. In: Byron PR, ed. Respiratory Drug Delivery. Boca Raton, FLA:CRC Press. 1990:67-206.
13. SanGiovanni ML. 3M reveals CFC-free inhaler for UK market. Spray Technol Marketing. 1995; 5(9):26-63.
14. Dalby RN. Halohydrocarbons: Pharmaceutical uses. In: Swarbrick J, Boylan JC, eds. Encyclopedia of Pharmaceutical Technology. New York:Marcel Dekker, 1993.
15. Whitham ME, Eagle AM. Alternative propellants: proprietary rights, toxicological issues and projected licensing problems. In: Byron PR, Dalby RN, Farr SJ, eds. Proceedings of Respiratory Drug Delivery IV. Buffalo Grove, IL: Interpharm Press, 1994:203-205.
16. Clark AR. The physics of aerosol formation by MDIs-limitations of the current approach. J Biopharm Sci. 1992; 3(1-2):69-76.
17. Smyth HDC, Hickey AJ. Multimodal particle size distributions emitted from HFA-134a solution pressurized metered-dose inhalers. AAPS PharmSciTech. 2003:4(3 article 38).
18. Hickey AJ, Dalby RN, Byron PR. Effects of surfactants on aerosol powders in suspension: Implications for airborne particle size. Int J Pharm 1988; 42(Mar):267-270.
19. Byron PR, Miller NC, Blondino FE, Visich JE, Ward GH. Some aspects of alternative propellant solvency. In: Byron PR, Dalby RN, Farr SJ, eds, Proceedings of Respiratory Drug Delivery IV. Buffalo Grove, IL: Interpharm Press, 1994:231-241.
20. Atkins PJ. The development of new solution metered dose inhaler delivery systems. In: Dalby RN, Evans R, eds. Proceedings of the Second Annual Respiratory Drug Delivery Symposium. Continuing Pharmacy Education, University of Kentucky, Lexington, KY. 1991:416-145.
21. Gonda I. Development of a systematic theory of suspension inhalation aerosols. I. A framework to study the effects of aggregation on the aerodynamic behaviour of drug particles. Int J Pharm 1985; 27:99-116.
22. Crowder TM, Rosati J, Shroeder J, Hickey AJ. Martonen TB. Fundamental effects of particle morphology on lung delivery: Predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 2002; 19(3):239-245.
23. Dalby RN, Phillips EM. Byron PN. Determination of drug solubility in aerosol propellants. Pharm Res 1991; 8(9):1206-1209.
24. Phillips EM, Byron PR, Dalby RN. Axial ratio measurements for early detection of crystal growth in suspension-type metered dose inhalers. Pharm Res 1993; 10(3):454-456.
25. Sirand C, Varlet JP, Hickey AJ. Aerosol-filling equipment for the preparation of pressurized-pack pharmaceutical formulations. In Pharmaceutical Inhalation Aerosol Technology. Hickey AJ. ed. New York:Marcel Dekker, Inc, 2004:311-344.
26. Schultz RK, Dupont RL, Ledoux KA. Issues surrounding metered dose valve technology: Past, present, and future perspectives. In: Byron PR, Dalby RN, Farr SJ, eds. Proceedings of Respiratory Drug Delivery IV. Buffalo Grove, IL: Interpharm Press, 1994:211-219. x
27. Byron PR, Dalby RN, Hickey AJ. Optimized inhalation aerosols. I. The effects of spherical baffle size and position upon the output of several pressurized nonaqueous suspension formulations. Pharm Res 1989; 6(3):225-229.
28. Dunbar CA, Hickey AJ. A new millennium for inhaler technology. Pharm Technol 1997; 21:116-125.
29. Ganderton D, Kassem NM. Dry powder inhalers. Adv Pharm Sci 1992; 6:165-191.
30. Hickey AJ, Concessio NM. Descriptors of irregular particle morphology and powder properties. Advanced Drug Del Rev 1997; 26:29-40.
31. Morley CJ, Miller N, Bangham AD, Davis JA. Dry artificial lung surfactant and its effect on very premature babies. Lancet 1981; 10:64-68.
32. Intal, cromolyn sodium, a monograph. Bedford, MA: Fisons Corp.
33. Taylor MK, Ginsburg J, Gheyas F, Hickey AJ. Composite method to quantify powder flow as a screening method in early tablet or capsule formulation development. AAPS PharmSciTech 2000:1(3).
34. Newman SP, Clarke SW. Therapeutic aerosols 1-physical and practical considerations. Thorax 1983; 38:881-886.
35. Gonda I. Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract. Crit Rev Ther Drug Carrier Syst 1990; 6:273-313.
36. Dunbar CA, Hickey AJ. Evaluation of probability density functions to approximate particle size distribution of representative pharmaceutical aerosols. J Aerosol Sci 2000; 31:813-831.
37. Hickey AJ. Targeting of pharmaceutical aerosols to the lung: what can be learned from inhalation toxicology and industrial hygiene? Sci Technol 1993; 18:290-304.
38. Schreier H, Mobley WC, Concessio N, Hickey AJ, Niven RW. Formulation and in vitro performance of liposome powder aerosols. STP Pharma Sciences 1994; 4:38-44.
39. Pillai RS, Yeates DB, Miller IF, Hickey AJ. Controlled release from condensation coated respirable aerosol particles. J Aerosol Sci 1994; 25:461-477.
40. Goldbach P, Brochart H, Stamm A. Spray-drying of liposomes for a pulmonary administration. I. Chemical stability of phospholipids. Drug Dev Ind Pharm 1993; 19(19):2611-2622.
41. Goldbach P, Brochart H, Stamm A. Spray-drying of liposomes for a pulmonary administration. II. Retention of encapsulated materials. Drug Dev Ind Pharm 1993; 19(19):2623-2636.
42. Louey MD, Van Oort MM, Hickey AJ. Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactose-blend formulations. Pharm Res 2004; 21(7):1207-1212.
43. Louey MD, Van oort MM and Hickey AJ. Aerosol dispersion of respirable particles in narrow size distributions produced by jet-milling and spray-drying techniques. Pharm Res 2004; 21(7):1200-1206.
44. Hickey AJ, Concessio NM, Van Oort MM, Platz RM. Factors influencing the dispersion of dry powders as aerosols. Pharm Technol 1994; 18(Pharm Technol):58-64, 82.
45. Sethuraman VV, Hickey AJ. Evaluation of preseparator performance for the eight-stage nonviable Andersen impactor. AAPS PharmSciTech 2001; 2(1 article 4).
46. Rietema K. The dynamics of fine powders. New York:Elsevier Science Publishing Co., Inc, 1991.
47. Suarez S and Hickey AJ. Drug properties affecting aerosol behavior. Respir Care 2000; 45(6):652-666.
48. Concessio NM, Hickey AJ. Analysis of the pattern of particle dispersion from a dry powder inhaler. Pharm Technol 1996; 20(6):50-62.
49. Fults KA, Miller IF, Hickey AJ. Effect of particle morphology on emitted dose of fatty acid-treated disodium cromoglycate powder aerosols. Pharm Dev Technol 1997; 2:67-79.
50. Byron PR, Jashnani R. Efficiency of aerosolization from dry powder blends of terbutaline sulfate and lactose NF with different particle size distributions. Pharm Res 1990; 7:881.
51. Ganderton D, Kassem N. Int. Patent Appl. #PCT GB91 00103 (Int. Publ. #WO 91/11179. Patent No.
52. Bell JH, Hartley PS, Cox JSG. Dry powder aerosols. I. A new powder inhalation device. J Pharm Sci 1971; 60:1559.
53. Concessio NM, Jager-Waldau R, Hickey AJ. Aerosol delivery from an active emission multisingle dose dry powder inhaler. Particulate Sci Tech 1997; 15:51-63.
54. Dunbar CA, Hickey AJ, Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA 1998; 16:7-44.
55. Ganderton D. The generation of respirable clouds from coarse powder aggregates. J Biopharm Sci 1992; 3:101-105.
56. Concessio NM, VanOort MM, Knowles M, Hickey AJ. Pharmaceutical dry powder aerosols: Correlation of powder properties with dose delivery and implications for pharmacodynamic effect. Pharm Res 1999; 16(6):828-834.
57. Hickey AJ. Summary of common approaches to pharmaceutical aerosol administration. In: Pharmaceutical Inhalation Aerosol Technology, Hickey AJ, ed. New York, NY: Marcel Dekker, Inc., 1992.
58. ® Turbuhaler and Berotec® dry powder inhaler. Allergy 1990; 45:382-385.
59. Wetterlin KIL. Turbuhaler: A new powder inhaler for administration of drugs to the airways. Pharm Res 1988; 5:506-508.
60. Rumpf H. Powder technology. London:Chapman and Hall, 1990.
61. Van Cleef. Powder technology. Am Sci 1991; 79:304-315.
62. Curry SH, Taylor AJ, Evans S, Godfrey S, Zeidifard E. Disposition of disodium cromoglycate administered in three particle sizes. J Pharm Pharmacol 1974; 26:79P-80P.
63. Mullins ME, Michaels LP, Menon V, Locke B, Ranade MB. Effect of geometry on particle adhesion. Aerosol Sci Technol 1992; 17:105-118.
64. Visser J. Van der waals and other cohesive forces affecting powder fluidization. Powder Technol 1989; 58:1-10.
65. Kontny MJ, Conners JJ, Graham ET. Moisture distribution and packaging of dry powder systems. In: Byron RN, Dalby RN, Farr SJ, eds. Respiratory Drug Delivery IV. Deerfield, IL: Interpharm Press, 1994:125-136.
66. Al-Chalabi SAM, Jones AR, Luckham PF. A simple method for improving the dispersability of micron-sized solid spheres. J Aerosol Sci 1990; 21(6):821-826.
67. Hickey AJ, Concessio NM. Aerodynamic behavior of micronized powders dispersed as aerosols. Pharm Technol 1994; 18:88, 90, 92, 94, 96, 98.
68. Vidgren M, Arppe J, Vidgren P, Vainio P, Silvasti M, Tukiainen H. Pulmonary deposition and clinical response of 99mTc-labelled salbutamol particles in healthy volunteers after inhalation from a metered-dose inhaler and from a novel multiple-dose powder inhaler. Pharm Res 1994; 11:1320-1324.
69. Corbett JS, Hart JL, Jansen R, Shephard MT, Wright P. Rotary planar multi-dose powder inhaler. J Aerosol Med 6(Suppl):72. AUTHOR PLEASE UPDATE
70. Wolff RK, Niven RW. Generation of aerosolized drugs. J Aerosol Med 1994; 7:89-106.
71. Anonymous. Dry powder inhalers-the shape of things to come? Pharm J 1992; 248:816-817.
72. Cheng Y, Barr EB, Yeh HC. A Venturi disperser as a dry powder generator for inhalation studies. Inhal Toxicol 1989; 1:365-371.
73. Jager-Waldau R, Mehring H, Wiggins JD. Feasibility of a low dosage dynamic powder disperser for drug delivery to the lungs. J Aerosol Med 1994; 7:205-208.
74. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing. J Aerosol Med 1993; 6:99-110.
75. Clark AR, Egan M. Modelling the deposition of inhaled powdered drug aerosols. J Aerosol Sci 1994; 25:175-186.
76. Auty RM, Brown K, Neale M, Snashall PD. Respiratory tract deposition of sodium cromoglyco-late is highly dependent upon technique of inhalation using the Spinhaler®. Br J Dis Chest. 1987; 81:371-380.
77. Pedersen S. How to use a Rotahaler©. Ann Arch Dis Child. 1986; 61:11-14.
78. Pedersen S, Steffenson G. Fenoterol powder inhaler technique in children: influence of inspira-tory flow rate and breath holding. Eur J Respir Dis. 1986; 68(3):207-214.
79. Spiro SG, Biddiscombe M, Marriott RJ, Short M, Taylor AJ. Inspiratory flow rates attained by asthmatic patients through a metered dose inhaler and a Diskhaler® inhaler. Br Med J (Clin Res Ed) 1992; 3:115-116.
80. Dunbar CA, Morgan B, Van Oort MM, Hickey AJ. A comparison of dry powder inhaler dose delivery characteristics using power. PDA J Pharm Sci Technol 2000; 54(6):478-484.
81. Newman SP, Moren F, Trofast E, Talaee N, Clarke SW. Terbutaline sulfate Turbuhaler: Effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm. 1991; 74(Aug 16):209-213.
82. Vidgren M, Karkkainen A, Karjalainen P, Paronen P, and Nuutinen J. Effect of powder inhaler design on drug deposition in the respiratory tract. Int J Pharm 1988; 42(Mar):211-216.
83. Vidgren M, Karkkainen A, Karjalainen P, Nuutinen J, Paronen P. In-vitro and in-vivo deposition of drug particles inhaled from pressurized aerosols and dry powder inhalers. Drug Dev Ind Pharm 1988; 14:2649-2665.
84. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990; 65(3):308-310.
85. Pedersen S. Clinical efficacy and safety of budesonide Turbuhaler as compared to MDIs in children. J Aerosol Med 1994; 75(Suppl 1):S67-71.
86. Schultz RK, Miller NC, Smith DK, Ross DL. Powder aerosols with auxiliary means of dispersion. J BioPharm Sci 1992; 3:115-121.
87. Hill M. Characteristics of an active multiple-dose dry powder inhaler. In: Byron PR, Dalby RN, Farr SJ, eds. Respiratory Drug Delivery IV. Buffalo Grove, IL:Interpharm Press, Inc, 1994:109-116.
88. Inhale Therapeutic Systems. Palo Alto, CA.
89. Staniforth JN. The importance of electrostatic measurements in aerosol formulation and preformulation. In: Respiratory Drug Delivery IV. Deerfield, IL: Interpharm Press, 1994.
90. National Heart, Lung and Blood Institue, Guidelines for the diagnosis and management of asthma, Bethseda, MD:NIH, 1992.
91. Polosa R, Finnerty JP. Inhalation of the propeller from a spinhaler. Eur Respir J 1991; 4(2):236-237.
92. Timsina MP, Martin GP, Marriott C, Ganderton D, Yianneskis M. Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm 1994; 101(Jan 1):1-13.
93. Timsina MP, Martin GP, Van Der Kolk H, Tushulzen E, Enthoben R. The effect of inhalation flow on the performance of a dry powder inhalation system. Int J Pharm 1992; 81:199-203.
94. Byron PR, Kelly EL, Lovering MJ, Poochikian GK, Sethi S, Theil CG. Recommendations of the USP Advisory Panel on the USP general chapters on Aerosols <601> and Uniformity of Doasge Units <905>. Pharm Forum 1994; 20:7477-7505.
95. Byron PR. Compendial dry powder testing: USP perspectives. In: Respiratory Drug Delivery IV. Deerfield, IL:Interpharm Press, 1994:153-162.
96. Hindle M, Byron PR. Measurement of the unit dose emitted from dry powder inhalers. Pharm Res 1993; 10:532.
97. Grossman J. The evolution of inhaler technology. J Asthma 1994; 31(1):55-64.
98. Tenholder MF, Whitlock WL. Can the nebulizer survive? Arch Intern Med 1993; 153(20):2389.
99. Newnham DM, Lipworth BJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream"). Thorax 1994; 49(8):762-770.
100. Baker PG, Stimpson PG. Electronically controlled drug delivery systems based on the piezoelectric crystal. In: Byron PR, Dalby RN, Farr SJ, eds. Proceedings of Respiratory Drug Delivery IV. Buffalo Grove, IL:Interpharm Press, 1994:273-285.
101. Crowder TM, Louey MD, Sethuraman VV, Smyth HDC, Hickey AJ. An odyssey in inhaler formulation and design. Pharm Technol 2001; 25(7):99-113.
102. Johnson CE. Principles of nebulizer - delivered drug therapy for asthma. Am J Hosp Pharm 1989; 46:1845-1855.
103. Clay MM, Clarke SW. Wastage of drug from nebulisers: Review. J R Soc Med 1987; 80:38-39.
104. Laube BL, Georgopoulos A, Adams GK. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA 1993; 269(16):2106-2109.
105. Niven RW. Pulmonary delivery of recombinant human granulocyte-colony stimulating facter (rhG-CSF). In: Byron PR, Dalby RN, Farr SJ. eds. Proceedings of Respiratory Drug Delivery IV. Buffalo Grove, IL:Interpharm Press, 1994:39-45.
106. Gupta S, Moussey F, Dalby RN, Miekka SI, Bruley DF. Pulmonary delivery of human protein C and factor IX. Advances in Experimental Medicine and Biology 1997; 411:429-435.
107. Taylor KM, Taylor G, Kellaway IW, Stevens J. Stability of liposomes to nebulization. Int J Pharm 1990; 58(Jan 15):57-61.
108. Masinde LE and Hickey AJ. Aerosolized aqueous suspensions of poly(L-lactic acid) micros-pheres. Int J Pharm 1993; 100(Nov 8):123-131.
109. Sterk PJ, Plomp A, Van de Vate JF, Quanjer PH. Physical properties of aerosols produced by several jet- and ultrasonic nebulizers. Bull Eur Physiopathol Respir 1984; 20(1):65-72.
110. Alvine GF, Rodgers P, Fitzsimmons KM, Ahrens RC. Disposable jet nebulizers. How reliable are they? Chest 1992; 101(2):316-319.
111. Reisman RE. Asthma induced by adrenergic aerosols. J Allergy Clin Immunol, 1973; 46:162-177.
112. Summers QA, Nesbit MR, Levin R, Holgate ST. A non-bronchoconstrictor, bacteriostatic preservative for nebuliser solutions. Br J Clin Pharmacol 1991; 31(2):204-206.
113. Toogood JH. Making better and safer use of inhaled steroids. J Respir Dis 1993; 14:221-238.
114. Clay MM, Pavia D, Newman SP, Lennard-Jones TL, Clarke SW. Assessment of jet nebulisers for lung aerosol therapy. Lancet 1983; 2(8350):592-594.
115. Kendrick AH, Smith EC, Denyer J. Nebulizers - fill volume, residual volume and matching of nebulizer to compressor. Respir Med 1995; 89(3):157-159.
116. Hidy GM, Brock JR. The dynamics of aerocolloidal systems. New York:Pergamon Press, 1970.
117. Nerbrink O, Dahlback M, Hansson HC. Why do medical nebulizers differ in their output and particle size. J Aerosol Med 1994; 7(3):259-276.
118. Cockcroft DW, Hurst TS, Gore BP. Importance of evaporative water losses during standardized nebulized. Chest 1989; 96(3):505-508.
119. Phipps PR, Gonda I. Droplets produced by medical nebulizers. Some factors affecting their size. Chest 1990; 97(6):1327-1332.
120. Mercer TT, Tillery MI, Chow HY. Operating characteristics of some compressed-air nebulizers. Am Ind Hyg Assoc J 1968; 29(1):66-78.
121. Clay MM, Pavia D, Newman SP, Clarke SW. Factors influencing the size distribution of aerosols from jet nebulizers. Thorax 1983; 38:755-759.
122. Newman SP, Pellow PGD. Evaluation of jet nebulizers. In: Ganderton D, Jones T, eds. Drug Delivery to the Respiratory Tract. New York:Ellis Horwood, 1987:125-132.
123. Childs HJ, Dezateux CA. A national survey of nebuliser use. Arch Dis Child, 1991; 66(11):1351-1353.
124. Erl B, Robbins P. Hand-held nebulization therapy. J Pediatr Nurs 1990; 5(6):408-409.
125. Allen TL, Dalby RN, McPherson ML. Evaluation of patient nebulizer use, measurement of nebulizer flow rate and output. In: Poster presented at the American Pharmaceutical Association Annual Meeting. Orlando, FL, 1994.
126. Merkus PJ, Van Essen-Zandvliet EE, Parlevliet E, Borsboom G, Sterk PJ, Kerrebijn KF, Quanjer PH. Changes of nebulizer output over the years. Eur Respir J 1992; 5(4):488-491.
127. Hollie MC, Malone RA, Skufca RM, Nelson HS. Extreme variability in aerosol output of the DeVilbiss 646 jet nebulizer. Chest 1991; 100(5):1339-1344.
128. Caldwell NA, Milroy R. Optimizing nebulization practice within a large teaching hospital: Easier. Respir Med 1995; 89(1):57-59.
129. Leflein J, Brown E, Hill M, Kelly HW, Loffert DT, Nelson HS, Szefler SJ. Delivery of glucocor-ticoids by jet nebulization: aerosol characteristics and output. J Allergy Clin Immunol 1995; 95(5 Pt 1):944-949.
130. Boucher RM, Kreuter J. The fundamentals of the ultrasonic atomization of medical solutions. Ann Allergy 1968; 26(11):591-600.
131. Lang RJ. Ultrasonic atomization of liquids. J Accous Soc Am 1962; 34:6-8.
132. Niven RW, Ip AY, Mittelman S, Prestrelski SJ, Arakawa T. Some factors associated with the ultrasonic nebulization of proteins. Pharm Res 1995; 12(1):53-59.
133. Dennis JH, Hendrick DJ. Design characteristics for drug nebulizers. J Med Eng Technol 1992; 16(2):63-68.
134. Dahlback M. Behavior of nebulizing solutions and suspensions. J Aerosol Med 1994; 7(Suppl 1):S13-18.
135. Olschewski H, Rohde B, Behr J, Ewer R, Gessler T, Ghofrani A, Schmehl T. Pharmacodynamics and pharmacokinetics of inhaled Iloprost, aerosolized by three different devices in severe pulmonary hypertension. Chest 2003; 124:1294-1304.
136. Brand P, Beckmann H, Enriquez MM, Meyer T, Müllinger B, Sommerer K, Weber N, Weuthen T, Scheuch G. Peripheral deposition of alpha 1-protease inhibitor using commercial inhalation devices. Eur Respir J 2003; 22:263-267.
137. Newth CJ, Clark AR. In vitro performance of the small particle aerosol generator (SPAG-2). Pediatr Pulmonol 1989; 7(3):183-188.
138. Sievers RE, Hybertson BM, Hansen BN. Methods and apparatus for drug delivery using supercritical solutions. US Patent #5,301,664. Patent No. 1994.